Amisulpride has a superior benefit/risk profile to haloperidol in schizophrenia: results of a multicentre, double-blind study (the Amisulpride Study Group). (Q53510568)
Jump to navigation
Jump to search
scientific article published in August 2000
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Amisulpride has a superior benefit/risk profile to haloperidol in schizophrenia: results of a multicentre, double-blind study (the Amisulpride Study Group). |
scientific article published in August 2000 |
Statements
Amisulpride has a superior benefit/risk profile to haloperidol in schizophrenia: results of a multicentre, double-blind study (the Amisulpride Study Group). (English)
Carrière P
Bonhomme D
Lempérière T
1 August 2000
15
5
321-329